伊立替康联合顺铂治疗晚期胃癌的临床观察  

Clinical observation of irinotecan combined with cisplatin in the treatment of advanced gastric cancer

作　　者：张从军[1] 钱勇[1] 熊福星[1] 郝吉庆[1] 

机构地区：[1]安徽医科大学第一附属医院肿瘤内科,合肥230022

出　　处：《临床肿瘤学杂志》2011年第4期359-361,共3页Chinese Clinical Oncology

摘　　要：目的观察伊立替康联合顺铂治疗晚期胃癌的疗效及毒副反应。方法 32例初治或复治晚期胃癌患者使用伊立替康和顺铂方案化疗。伊立替康150~180mg/m2,静滴90min,d1;顺铂25mg/m2,静滴,d1~d3。21天为1周期,至少完成2个周期。结果 32例均可评价疗效,获CR 1例（3.1%）,PR 11例（34.4%）,SD 11例（34.4%）,PD 9例（28.1%）,有效率为37.5%（12/32）。中位疾病进展时间为6.8个月,中位生存时间为12.4个月。主要毒副反应为恶心、呕吐、迟发性腹泻、乙酰胆碱综合征、中性粒细胞减少等,多为1~2级。结论伊立替康联合顺铂是晚期胃癌初治或复治患者的有效治疗方案,不良反应可耐受,值得临床进一步研究。Objective To evaluate the efficacy and adverse effects of irinotecan（CPT-11） combined with cisplatin（DDP） in the treatment of patients with advanced gastric cancer.Methods Thirty-two cases of initial treatment and retreatment with advanced gastric cancer received chemotherapy.Irinotican was administered at 150-170mg/m2 by 90 min infusion on d1.Cisplatin was administered at 25mg/m2 by infusion on d1-d3.Every 21 days was one cycle and at least 2 cycles were given.Results Thirty-two patients could be evaluated for efficacy.The response rate was 37.5%（12/32） with 1 CR（3.1%）,11 PR（34.4%）,11 SD（34.4%）and 9 PD（28.1%）.The median time to progression was 6.8 months and the median survival time was 12.4 months.The main adverse effects was nausea,vomiting,delayed diarrhea,acetylcholine syndrome and neutropenia,and most of them were degree 1-2.Conclusion Irinotecan combined with cisplatin is available,and adverse effects are tolerated for advanced gastric cancer.The combination of irinotecan and cisplatin deserves clinical expansion and further exploration.

关 键 词：伊立替康 顺铂 晚期胃癌 化学治疗 

分 类 号：R735.2[医药卫生—肿瘤]